Rational Design of AAV-rh74, AAV3B, and AAV8 with Limited Liver Targeting

Area of Science:

• Gene Therapy
• Molecular Virology
• Biotechnology

Background:

• Recombinant adeno-associated viruses (rAAVs) are leading gene therapy vectors.
• Most rAAV serotypes exhibit high liver transduction upon peripheral administration, limiting non-liver tissue targeting.
• AAVHSC16 is a notable exception with minimal liver tropism.

Purpose of the Study:

• To develop novel rAAV capsids with reduced liver transduction.
• To address the challenge of liver tropism in peripheral rAAV gene therapy.
• To create liver-de-targeted rAAV vectors through rational capsid design.

Main Methods:

• Utilized data from the naturally occurring AAVHSC16 capsid.
• Employed rational design principles for engineering new rAAV capsids.
• Focused on creating non-clade F rAAV capsids.

Main Results:

• Successfully designed four novel non-clade F rAAV capsids.
• These engineered capsids demonstrated reduced liver transduction following peripheral injection.
• The findings support the potential for improved tissue-specific gene delivery.

Conclusions:

• Rational design based on AAVHSC16 is effective for reducing rAAV liver tropism.
• The developed capsids offer potential for enhanced non-liver tissue targeting in gene therapy.
• This work contributes to the development of safer and more effective rAAV-based therapies.